Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04305613 · ClinicalTrials.gov registry record
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
A clinical trial of Radiation Toxicity and Cardiotoxicity, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- 221
- Enrollment target
- 8
- Study locations
NCT04305613 is a study of Radiation Toxicity and Cardiotoxicity that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 221 participants, below the 455-participant average among 12 other Radiation Toxicity trials with a reported enrollment target (51% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT04305613, a study of Radiation Toxicity and Cardiotoxicity, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 221 participants
- Enrollment target
- 8
- Study locations
Study Summary
This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. Patients will be enrolled prior to the start of therapy and followed during and for at least 2 years after therapy with echocardiograms, nuclear stress tests, blood sampling, and quality of life surveys.
Conditions Studied
Interventions
- OTHER Chemoradiation
Study Locations (8)
Pennsylvania
- Lancaster General Hospital - Lancaster
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
- Chester County Hospital - West Chester
Alabama
- University of Alabama - Birmingham
Massachusetts
- The Brigham and Women's Hospital - Boston
Missouri
- Washington University School of Medicine - St Louis
New Jersey
- Rutger's University / Cancer Institute of New Jersey - New Brunswick
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2030-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04305613
The ClinicalTrials.gov registry entry for NCT04305613 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 455-participant average among 12 other Radiation Toxicity trials with a reported enrollment target (51% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Radiation Toxicity appearing as the primary indexed condition, and to 1 intervention - of which Chemoradiation is the first listed.
NCT04305613 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Pennsylvania, Alabama, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04305613 about?
NCT04305613 is a clinical study titled "Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy". This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. Patients will be enrolled prior to the start of therapy and followed during and for at least 2 years after therapy with echocardiograms, nuclear stress tes...
What is the current status of trial NCT04305613?
This trial is currently active not recruiting. The enrollment target is 221 participants. The study started on 2020-09-14. Estimated completion is 2030-12.
What conditions does trial NCT04305613 study?
This clinical trial studies the following conditions: Radiation Toxicity, Cardiotoxicity, Lung Cancer Stage II, Lung Cancer Stage III.
What interventions are being tested in trial NCT04305613?
The interventions under investigation include: Chemoradiation (OTHER).
Who is sponsoring clinical trial NCT04305613?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04305613 being conducted?
This trial has 8 study locations across Alabama, Massachusetts, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Radiation Toxicity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy
RECRUITING · NA
-
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
RECRUITING · Early Phase 1
-
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
RECRUITING · Phase 1
-
Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
ACTIVE NOT RECRUITING
-
Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
ACTIVE NOT RECRUITING
-
Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.